JPWO2021252517A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021252517A5 JPWO2021252517A5 JP2022575767A JP2022575767A JPWO2021252517A5 JP WO2021252517 A5 JPWO2021252517 A5 JP WO2021252517A5 JP 2022575767 A JP2022575767 A JP 2022575767A JP 2022575767 A JP2022575767 A JP 2022575767A JP WO2021252517 A5 JPWO2021252517 A5 JP WO2021252517A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- polypeptide
- seq
- amino acid
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063036539P | 2020-06-09 | 2020-06-09 | |
| US63/036,539 | 2020-06-09 | ||
| PCT/US2021/036443 WO2021252517A1 (en) | 2020-06-09 | 2021-06-08 | Engineered t cell receptors and methods of use |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023530245A JP2023530245A (ja) | 2023-07-14 |
| JP2023530245A5 JP2023530245A5 (https=) | 2024-06-07 |
| JPWO2021252517A5 true JPWO2021252517A5 (https=) | 2024-06-07 |
| JP7827645B2 JP7827645B2 (ja) | 2026-03-10 |
Family
ID=78845879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022575767A Active JP7827645B2 (ja) | 2020-06-09 | 2021-06-08 | 操作されたｔ細胞受容体および使用の方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230227526A1 (https=) |
| EP (1) | EP4161555A4 (https=) |
| JP (1) | JP7827645B2 (https=) |
| CN (1) | CN116096740A (https=) |
| CA (1) | CA3186594A1 (https=) |
| WO (1) | WO2021252517A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120718134B (zh) * | 2025-08-25 | 2025-12-26 | 北京立康生命科技有限公司 | 靶向col6a3肽的t细胞受体及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050010030A1 (en) * | 2003-07-02 | 2005-01-13 | Zang Jingwu Z. | T cell receptor CDR3 sequence and methods for detecting and treating rheumatoid arthritis |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| IL290655B2 (en) * | 2014-05-29 | 2024-05-01 | Us Health | Anti-human papillomavirus 16 E7 T-cell chelates |
| EP3156067A1 (en) * | 2015-10-16 | 2017-04-19 | Max-Delbrück-Centrum Für Molekulare Medizin | High avidity hpv t-cell receptors |
| EP3452514A1 (en) * | 2016-05-06 | 2019-03-13 | Fred Hutchinson Cancer Research Center | T-cell immunotherapy specific for mart-1 |
| DE102016115246C5 (de) * | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| TW201835100A (zh) * | 2017-02-06 | 2018-10-01 | 國立研究開發法人國立癌症研究中心 | 新穎ｔ細胞受體 |
| AU2018318303A1 (en) * | 2017-08-18 | 2020-04-09 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
| EP4219543A1 (en) * | 2017-11-06 | 2023-08-02 | Immatics Biotechnologies GmbH | Novel engineered t cell receptors and immune therapy using the same |
| AU2019249209A1 (en) * | 2018-04-05 | 2020-10-15 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
-
2021
- 2021-06-08 CN CN202180057372.6A patent/CN116096740A/zh active Pending
- 2021-06-08 WO PCT/US2021/036443 patent/WO2021252517A1/en not_active Ceased
- 2021-06-08 CA CA3186594A patent/CA3186594A1/en active Pending
- 2021-06-08 US US18/001,185 patent/US20230227526A1/en active Pending
- 2021-06-08 EP EP21822596.9A patent/EP4161555A4/en not_active Withdrawn
- 2021-06-08 JP JP2022575767A patent/JP7827645B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102764123B1 (ko) | Τ 세포 수용체 및 이를 발현하는 조작된 세포 | |
| KR102669749B1 (ko) | 키메라 사이토카인 수용체 | |
| US10118964B2 (en) | Construction and application of bispecific antibody HER2xCD3 | |
| CN113286879A (zh) | 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子 | |
| CN118580363A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| US20250073266A1 (en) | Dosing regimens for cancer immunotherapy | |
| CN111556756A (zh) | 重组免疫细胞、制备方法和使用方法 | |
| CN115279784A (zh) | 针对含有g12d突变的ras的hla i类限制性t细胞受体 | |
| CN117083301A (zh) | 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用 | |
| CN120584131A (zh) | 针对prame肽-hla复合物的结合分子 | |
| TW202309083A (zh) | 抗ｃｌｄｎ４－抗ｃｄ１３７雙特異性抗體 | |
| CN114369168B (zh) | 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法 | |
| CN120530140A (zh) | 针对piwil1肽-hla复合物的结合分子 | |
| JPWO2021236548A5 (https=) | ||
| JP7505784B2 (ja) | Ｇｄ２結合性分子 | |
| JPWO2021252517A5 (https=) | ||
| JPWO2022098845A5 (https=) | ||
| CN111434691A (zh) | Pd-l2单克隆抗体及其应用 | |
| CN116157528B (zh) | 抗原结合蛋白及其用途 | |
| CN119613563A (zh) | 编码car的核酸分子和含其的载体、car、含car的免疫细胞及其制造方法和含该细胞的医药组合物及提升细胞损伤活性的方法 | |
| CN117924519A (zh) | 靶向cd138的嵌合抗原受体 | |
| KR20250084957A (ko) | T세포성 종양의 치료제 | |
| CN117683138A (zh) | 包含靶向cd38的多靶点嵌合抗原受体 | |
| JPWO2023076863A5 (https=) | ||
| CN121293358B (zh) | 结合EpCAM的纳米抗体、嵌合抗原受体及其应用 |